<DOC>
	<DOCNO>NCT01802268</DOCNO>
	<brief_summary>Background Early conversion calcineurin inhibitor mammalian target rapamycin inhibitor one immunosuppressive strategy investigate mitigate long-term CNi associate adverse event . This study aim evaluate conversion tacrolimus sirolimus de novo kidney transplant recipient . This multicenter , open-label study , plan enroll 297 patient initially treat tacrolimus , enteric-coated mycophenolate sodium ( 1440 mg/day , orally ) prednisone . The primary objective show superior glomerular filtration rate SRL group 24 month transplantation .</brief_summary>
	<brief_title>Planned Conversion From TAC SRL-based Regimen de Novo Kidney Transplant Recipients</brief_title>
	<detailed_description />
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>patient older 18 year , recipient first kidney transplant brain dead decease living relate nonHLA identical donor older 65 year , patient receive ABO compatible organ CDC negative crossmatch peak panel reactive antibody lower 30 % , patient agree use contraceptive method study 3 month study drug discontinuation . patient chronic kidney disease due focal segmental glomerulosclerosis membranoproliferative glomerulonephritis , patient active infection positive hepatitis B C human immunodeficiency virus , patient previous history malignancy , patient significant hematological metabolic laboratorial abnormality .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>sirolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>early conversion</keyword>
</DOC>